InMed Pharmaceuticals Inc.INMNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank50
3Y CAGR-17.9%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-17.9%/yr
vs -27.4%/yr prior
Acceleration
+9.5pp
Accelerating
Percentile
P50
Within normal range
vs 3Y Ago
0.6x
Contraction
Streak
2 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 13.10% |
| 2024 | -0.84% |
| 2023 | -14.85% |
| 2022 | 23.66% |
| 2021 | 75.93% |
| 2020 | -47.42% |
| 2019 | 16.16% |
| 2018 | 85.19% |
| 2017 | 88.93% |
| 2016 | -43.64% |